These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38140540)

  • 1. Antiviral Potential of Azelastine against Major Respiratory Viruses.
    Fischhuber K; Bánki Z; Kimpel J; Kragl N; Rössler A; Bolze A; Muellauer B; Angerer J; Nagy G; Nagy E; Szijarto V
    Viruses; 2023 Nov; 15(12):. PubMed ID: 38140540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Anti-Histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits Infection by Major Variants of SARS-CoV-2 in Cell Cultures and Reconstituted Human Nasal Tissue.
    Konrat R; Papp H; Kimpel J; Rössler A; Szijártó V; Nagy G; Madai M; Zeghbib S; Kuczmog A; Lanszki Z; Gesell T; Helyes Z; Kemenesi G; Jakab F; Nagy E
    Front Pharmacol; 2022; 13():861295. PubMed ID: 35846988
    [No Abstract]   [Full Text] [Related]  

  • 3. Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus.
    Al-Beltagi S; Preda CA; Goulding LV; James J; Pu J; Skinner P; Jiang Z; Wang BL; Yang J; Banyard AC; Mellits KH; Gershkovich P; Hayes CJ; Nguyen-Van-Tam J; Brown IH; Liu J; Chang KC
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33546185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication.
    Tripp RA; Martin DE
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza A(H1N1)pdm09 Virus but Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during Sequential Infections in Human Nasal Epithelial Cells.
    Fage C; Hénaut M; Carbonneau J; Piret J; Boivin G
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
    Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
    Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus.
    Leneva I; Kartashova N; Poromov A; Gracheva A; Korchevaya E; Glubokova E; Borisova O; Shtro A; Loginova S; Shchukina V; Khamitov R; Faizuloev E
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.
    Ge S; Lu J; Hou Y; Lv Y; Wang C; He H
    Virology; 2021 Aug; 560():110-115. PubMed ID: 34052578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity.
    Nittayananta W; Lerdsamran H; Chutiwitoonchai N; Promsong A; Srichana T; Netsomboon K; Prasertsopon J; Kerdto J
    Virol J; 2024 Jan; 21(1):26. PubMed ID: 38263162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hylin-a1: A Pan-Inhibitor against Emerging and Re-Emerging Respiratory Viruses.
    Chianese A; Zannella C; Monti A; Doti N; Sanna G; Manzin A; De Filippis A; Galdiero M
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4'-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses.
    Lieber CM; Aggarwal M; Yoon JJ; Cox RM; Kang HJ; Sourimant J; Toots M; Johnson SK; Jones CA; Sticher ZM; Kolykhalov AA; Saindane MT; Tompkins SM; Planz O; Painter GR; Natchus MG; Sakamoto K; Plemper RK
    PLoS Pathog; 2023 Apr; 19(4):e1011342. PubMed ID: 37068076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication.
    Sourimant J; Lieber CM; Aggarwal M; Cox RM; Wolf JD; Yoon JJ; Toots M; Ye C; Sticher Z; Kolykhalov AA; Martinez-Sobrido L; Bluemling GR; Natchus MG; Painter GR; Plemper RK
    Science; 2022 Jan; 375(6577):161-167. PubMed ID: 34855509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia.
    Fais F; Juskeviciene R; Francardo V; Mateos S; Guyard M; Viollet C; Constant S; Borelli M; Hohenfeld IP
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses.
    Park JG; Ávila-Pérez G; Nogales A; Blanco-Lobo P; de la Torre JC; Martínez-Sobrido L
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.
    Klussmann JP; Grosheva M; Meiser P; Lehmann C; Nagy E; Szijártó V; Nagy G; Konrat R; Flegel M; Holzer F; Groß D; Steinmetz C; Scherer B; Gruell H; Schlotz M; Klein F; de Aragão PA; Morr H; Al Saleh H; Bilstein A; Russo B; Müller-Scholtz S; Acikel C; Sahin H; Werkhäuser N; Allekotte S; Mösges R
    Sci Rep; 2023 Apr; 13(1):6839. PubMed ID: 37100830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural Derived Nasal Spray; A Proposed Approach for COVID-19 Disease Control.
    Hoseini-Tavassol Z; Ejtahed HS; Soroush AR; Sajjadpour Z; Hasani-Ranjbar S; Larijani B
    Infect Disord Drug Targets; 2021; 21(8):e160921191568. PubMed ID: 33602078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
    Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of influenza A virus and SARS-CoV-2 infection or co-infection by griffithsin and griffithsin-based bivalent entry inhibitor.
    Cao N; Cai Y; Huang X; Jiang H; Huang Z; Xing L; Lu L; Jiang S; Xu W
    mBio; 2024 May; 15(5):e0074124. PubMed ID: 38587427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory Syncytial Virus Protects Bystander Cells against Influenza A Virus Infection by Triggering Secretion of Type I and Type III Interferons.
    Czerkies M; Kochańczyk M; Korwek Z; Prus W; Lipniacki T
    J Virol; 2022 Nov; 96(22):e0134122. PubMed ID: 36326278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.
    Li P; Kim Y; Dampalla CS; Nhat Nguyen H; Meyerholz DK; Johnson DK; Lovell S; Groutas WC; Perlman S; Chang K-O
    mBio; 2024 Feb; 15(2):e0287823. PubMed ID: 38126789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.